HighTide Therapeutics Inc

02511

Company Profile

  • Business description

    HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

  • Contact

    Ganli Second Road
    18B-102, Zhonghaixin Innovation Industry City
    Jihua Neighborhood
    Longgang District, Guangdong
    Shenzhen518112
    CHN

    https://www.hightidetx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    68

Stocks News & Analysis

stocks

2 undervalued ASX shares report

These two ASX shares are trading at a discount to our fair value. 
stocks

Turmoil at WiseTech

Board members step down over differences on the role of former CEO Richard White.
video

What does the RBA rate cut mean for investors?

Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,494.5065.60-0.77%
CAC 408,090.9963.52-0.78%
DAX 4022,425.93138.370.62%
Dow JONES (US)43,461.2133.190.08%
FTSE 1008,658.980.39-0.00%
HKSE22,998.69342.92-1.47%
NASDAQ19,286.93237.08-1.21%
Nikkei 22538,345.99430.95-1.11%
NZX 50 Index12,355.74175.98-1.40%
S&P 5005,983.2529.88-0.50%
S&P/ASX 2008,247.0061.20-0.74%
SSE Composite Index3,359.2713.76-0.41%

Market Movers